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Context: The relationship between low-penetrance genes, metabolic risk factors, and levels of
endogenous 17-estradiol and progesterone, which play a role in breast cancer risk, remains unclear.
Objective: The aim of this study was to determine whether common polymorphisms in CYP17, in combi-
nationwithmetabolicriskfactors(individuallyorclustered),altersalivaryconcentrationsoffreebiologically
active 17-estradiol and progesterone among healthy premenopausal Norwegian women.
Design: Eight single nucleotide polymorphisms in CYP17 were genotyped in 203 healthy premeno-
pausal women aged 25–35 yr in the Norwegian EBBA-I Study, conducted in 2000–2002. Daily salivary
concentrations of 17-estradiol and progesterone were measured throughout one menstrual cycle. A
clusteredmetabolic scorewascalculated, includingwaist circumference,meanarterialpressure, insulin
resistance, fasting triglycerides, and total cholesterol/high-density lipoprotein cholesterol ratio. The
study hypothesis was tested in multivariable linear regression and generalized estimating equation
models.
Results: Women in the upper tertile of clustered metabolic score with the CYP17 rs2486758 minor
allele had daily salivary 17-estradiol concentrations that were 53% higher than other study
women throughout the menstrual cycle (P  0.001). Similarly, women in the upper tertile of total
cholesterol/high-density lipoprotein cholesterol ratio, fasting triglycerides, and insulin resistance
had 44, 32, and 24% higher daily salivary 17-estradiol concentrations, respectively (all P  0.05).
Conclusion: The CYP17 rs2486758 minor allele may predispose to higher 17-estradiol levels, par-
ticularly in premenopausal women with a high clustered metabolic score. Thus, modification of
metabolic risk factors may have significant implications for the prevention of breast cancer in
women with the minor allele of CYP17 rs2486758. (J Clin Endocrinol Metab 97: E852–E857, 2012)
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Exposure to ovarian hormones is critical to breast can-cer development; the genes that control estrogen and
progesterone biosynthesis in the ovaries may contribute to
inherent variability in breast cancer susceptibility. The
present study focuses on CYP17, which is expressed in
ovarian theca cells and encodes cytochrome P450 enzymes
that control the early steps of endogenous estrogen bio-
synthesis by converting progesterone into precursors of
estrogen.
So far, reports have failed to demonstrate a consistent
relationship between CYP17 genotype and levels of ovar-
ian hormones in premenopausal women (1–4) or breast
cancer risk (5, 6). However, mainly rs743572, which is a
single nucleotide polymorphism (SNP) located in the pro-
moter region of CYP17, has been studied, whereas recent
evidence indicates that SNPs in noncoding regions of a
gene may effect gene expression. Interestingly, when strat-
ifying by body mass index, Small et al. (2) documented an
association between CYP17 rs743572 and serum estra-
diol concentration among leaner women. Importantly,
metabolic risk factors (i.e. body fatness, hypertension,
dyslipidemia, and insulin resistance) increase levels of
ovarian hormones (7–10) and breast cancer risk (5, 6), but
little is known about interacting effects of genetic predis-
position caused by other common SNPs in CYP17.
Based on these previous studies, there is a need for fur-
ther investigations to address possible modifying effects of
metabolic risk factors on the association between common
SNPs in CYP17 and ovarian hormones. Therefore, the
main aim of this study was to examine whether eight SNPs
in CYP17, in combination with higher levels of metabolic
risk factors (individually or clustered), are associated with
increased daily salivary 17-estradiol and progesterone
concentrations in healthy premenopausal women with
regular ovulatory cycles.
Subjects and Methods
Participants and study design
The Norwegian Energy Balance and Breast Cancer Aspects
(EBBA-I) Study was conducted in 2000–2002 and included 204
women aged 25–35 yr with regular menstrual cycles (length,
20–40 d) who did not use any daily medication; were not preg-
nant, lactating, or using steroid contraceptives in the 6 months
before recruitment; and had no gynecological or chronic disor-
ders (7). Characteristics including reproductive history and life-
style factors were collected using questionnaires at the time of
recruitment. One woman was excluded due to low call frequency
in the genotyping analysis; thus, 203 participants are included in
this report. All participants gave written informed consent, and
ethical approval was obtained for the study.
Clinical examination and collection of blood
samples
All participants underwent clinical examination at the
Clinical Research Center, University Hospital of North Nor-
way, Tromsø, Norway, at three scheduled visits during their
menstrual cycle. The present report considered measures from
the first visit only. Morning blood samples were taken at the
first scheduled visit (between d 1 and 5 of the menstrual cycle),
after a fasting period that started at 2400 h and included
abstaining from smoking and exercise. Details of the EBBA-I
Study, anthropometric measurements, and serum lipids, glu-
cose and SHBG assays have been described (7) and are in-
cluded in the Supplemental Materials and Methods (published
on The Endocrine Society’s Journals Online web site at
http://jcem.endojournals.org).
Collection and analysis of saliva samples
Participants self-collected daily morning saliva samples at
home for one entire menstrual cycle, starting on the first day of
bleeding (7, 11).
Salivary 17-estradiol concentration was assayed for 20 d
and progesterone for 14 d of the menstrual cycle, using I-125-
based RIA kits (see Supplemental Materials and Methods for
details). All cycles were aligned at midcycle based on the iden-
tification of the drop in 17-estradiol concentration (aligned
cycle day 0), which provides a reasonable estimate of the day of
ovulation (11). Satisfactory identification of the drop in salivary
17-estradiol concentration could not be made for 14 women.
For the remaining 189 women, a “late-follicular” index (mean
value aligned cycle days 5 to 1), a “luteal” index (mean value
aligned cycle days 0 to  6), and a “mid-menstrual” index (mean
value aligned cycle days 7 to  6) were calculated. Maximum
peak level refers to the highest measured hormone value during
the menstrual cycle (aligned cycle day 1).
SNP selection and genotyping
To represent the variability in CYP17 in Caucasians, eight of
its SNP (rs1004467, rs743575, rs4919687, rs3781286,
rs3824755, rs10786712, rs743572, and rs2486758) were se-
lected using the Genome Variation Server (LDSelect). Criteria for
SNP selection were an r2 threshold of 0.8 and a minor allele
frequency greater than 5%. Genotyping was performed using the
Illumina Golden Gate Platform (Illumina Inc., San Diego, CA).
Homo- and heterozygote genotypes of the minor allele were
combined into one category, using the homozygote genotype of
the major allele as the reference category (dominant model). Five
SNPs in CYP17 were not associated with ovarian hormones, and
interactions with metabolic risk factors were not observed in
crude analyses. Another two (rs743575, rs4919687) were
weakly associated with overall mean salivary 17-estradiol con-
centration in crude analyses, but no interactions with metabolic
risk factors were observed. Therefore, these seven SNPs were
considered less suitable for the main aim of this report and were
discarded. One SNP in CYP17 (rs2486758) was associated with
overall mean salivary 17-estradiol concentrations in crude
analyses and was therefore used in further analyses. Further in-
formation about SNP selection, as well as details about geno-
typing and quality control including allele frequencies and a link-
age disequilibrium plot, is reported in the Supplemental
Materials and Methods, Supplemental Table 1, and Supplemen-
tal Fig. 1.
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Statistical analyses
Statistical analyses were performed using STATA version SE
11.0 (StataCorp., College Station, TX). The statistical signifi-
cance level was defined as P  0.05. More details are available
in the Supplemental Materials and Methods and Supplemental
Table 3.
Descriptive analyses
Student’s t test and Pearson’s 2 test were used to compare
means and proportions of selected characteristics of the partic-
ipants by genotype. The homeostatic model assessment
(HOMA) score [fasting glucose (mmol/liter)  fasting insulin
(IU/ml)]/22.5 was used as an indicator of insulin resistance. We
constructed a clustered metabolic score by summarizing z-scores
[(individual raw values  sample mean)/sample SD] of the fol-
lowing variables for each woman: waist circumference, fasting
triglycerides, total cholesterol/high-density lipoprotein choles-
terol (HDL-C) ratio, HOMA score, and mean arterial pressure
[(diastolic blood pressure  2)  systolic blood pressure]/3. Met-
abolic score was considered a continuous variable with a mean
score of 0, so that lower values corresponded to a more favorable
profile.
Analyses of single SNP
Linear regression and generalized estimating equation models
were used to evaluate associations between CYP17 SNP and
salivary ovarian hormone concentrations. All hormone values
were log-transformed before the statistical analyses. Possible in-
teractions between CYP17 SNP were evaluated by multiplicative
terms in the models with age as the only covariate. Wald 2 test
statistics was used to assess the associations between CYP17
rs2486758 genotypes, metabolic risk factors, and daily salivary
17-estradiol concentrations. The study population was homo-
geneously Caucasian; thus, ethnicity was not included in the
model as a covariate. Participants were stratified by tertiles of
metabolic risk factors (individual and clustered).
TABLE 1. Characteristics of the Norwegian EBBA-I Study population by CYP17 rs2486758 genotypes (n  203)a
Major alleleb Minor alleleb P valuec
n 121 82
Age (yr) 30.7 (30.1, 31.2) 30.8 (30.1, 31.4) 0.85
Age at menarche (yr) 13.0 (12.8, 13.3) 13.3 (12.9, 13.6) 0.25
Cycle length (d) 28.5 (28.0, 29.1) 27.8 (27.0, 28.5) 0.087
Energy intake (kJ/d) 8192 (7853, 8531) 7915 (7494, 8336) 0.31
Alcohol (units/wk) 3.26 (3.03, 3.49) 3.14 (2.85, 3.42) 0.50
Current smokers (%) 23.1 20.7 0.69
Sedentary activity in leisure time (%) 59.4 40.6 0.98
Body composition
BMI (kg/m2) 24.2 (23.6, 24.9) 24.5 (23.7, 25.4) 0.59
Waist circumference (cm) 79.0 (77.3, 80.7) 79.9 (77.8, 82.0) 0.54
Clinical measurements
Systolic blood pressure (mm Hg) 112.5 (110.4, 114.6) 114.4 (112.1, 116.7) 0.23
Diastolic blood pressure (mm Hg) 70.5 (68.9, 72.0) 71.5 (70.0, 73.1) 0.37
Serum concentrationsd
Total cholesterol (mmol/liter) 4.48 (4.34, 4.63) 4.39 (4.23, 4.55) 0.41
HDL-C (mmol/liter) 1.55 (1.49, 1.61) 1.53 (1.45, 1.60) 0.64
Total cholesterol/HDL-C ratio 3.00 (2.86, 3.15) 3.00 (2.82, 3.18) 0.97
Triglycerides (mmol/liter) 0.78 (0.70, 0.86) 0.99 (0.64, 1.34) 0.17
Glucose (mmol/liter) 4.97 (4.87, 5.07) 5.09 (4.96, 5.22) 0.15
Insulin (pmol/liter) 85.2 (72.9, 97.4) 84.1 (75.9, 92.3) 0.90
SHBG (nmol/liter)e 52.6 (49.1, 56.2) 51.0 (46.7, 55.3) 0.57
Clustered metabolic scoref 2.07 (1.44, 2.70) 2.91 (1.97, 3.85) 0.13
Saliva concentrations (pmol/liter)e
Overall 17-estradiolg 13.0 (11.8, 14.3) 15.4 (13.7, 17.2) 0.026
Late follicular index 17-estradiolh 16.7 (15.0, 18.6) 18.4 (16.2, 21.0) 0.11
Luteal index 17-estradioli 13.9 (12.3, 15.6) 16.4 (14.3, 18.8) 0.035
Overall progesteroneg 90.0 (78.8, 102.8) 101.4 (87.3, 117.7) 0.24
Data are expressed as mean (95% confidence interval) or percentage unless otherwise specified. BMI, Body mass index.
a Number may vary due to missing information.
b Major allele, homozygote; minor allele, hetero- and homozygote.
c Student’s t test or Pearson’s 2 test, linear regression, or generalized estimating equation with log-transformed hormones as dependent variable.
d Fasting serum measurements at d 1–5 after onset of menstrual cycle.
e Data represent age-adjusted geometric means (95% confidence interval).
f Estimated from waist circumference, fasting triglycerides, total cholesterol/HDL-C ratio, mean arterial pressure (diastolic blood pressure  2) 
systolic blood pressure]/3, and HOMA score fasting glucose (mmol/liter)  fasting insulin (IU/ml)/22.5.
g Genotypes equally distributed among women with and without identified drop day.
h Aligned cycle day 5, 1 (n  189).
i Aligned cycle day 0, 6 (n  189).
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Haplotype analyses of multiple SNP
Haplotype analyses were performed by using SNPStats soft-
ware (Catalan Institute of Oncology, IDIBELL, Epidemiology
and Cancer Registry L’Hospitalet, Barcelona, Spain) (12). The
eight selected SNP formed nine common haplotypes (frequency
 0.5%) in our study population. Likelihood ratio test was used
to assess the association between the haplotypes and salivary
17-estradiol concentration.
Results
Analyses of a single SNP
CYP17 rs2486758 genotype and ovarian hormones
Participants with the CYP17 rs2486758 minor allele had
an 18.5% higher overall salivary 17-estradiol concentra-
tion (P  0.026), and an 18.0% higher luteal index (P 
0.035), compared with women with the homozygote geno-
type of the major allele (Table 1). Analyses of salivary 17-
estradiol concentration by aligned cycle day are reported in
Supplemental Table 2 and Supplemental Fig. 2. CYP17
rs2486758 genotype was not associated with salivary pro-
gesterone and serum SHBG concentrations (Table 1).
Comparison across tertiles of metabolic risk factors:
CYP17 rs2486758 genotype and 17-estradiol
For participants in the upper tertile of metabolic risk fac-
tors with the minor allele, we observed an increase in daily
salivary 17-estradiol concentration throughout the men-
strual cycle: 24% for HOMA score (P  0.021), 32% for
fasting triglycerides (P  0.004), 44% for total cholesterol/
HDL-C ratio (P  0.005), and 53% for clustered metabolic
score(P0.001),comparedwithallotherwomencombined
(Fig. 1). CYP17 rs2486758 was not associated with serum
SHBG concentration among women in the upper tertile of
the clustered metabolic score (P  0.19).
Comparison within the upper tertile of metabolic risk
factors: CYP17 rs2486758 genotype and 17-estradiol
For women in the upper tertile of metabolic risk factors,
the minor allele was associated with an increase in daily sal-
ivary 17-estradiol concentration of 29% for fasting triglyc-
erides (P  0.040), 35% for total cholesterol/HDL-C ratio
(P  0.039), and 38% for clustered metabolic score (P 
0.004) compared with women in the upper tertile of meta-
bolic risk factors carrying the major allele (Fig. 1). The
increase in peak salivary 17-estradiol concentration was
36% (P  0.024) for clustered metabolic score (Fig. 1F).
Haplotype analyses
One specific haplotype was associated with increased
salivary 17-estradiol concentration (P  0.0045). There
was no significant difference in salivary 17-estradiol con-
centration between haplotypes (global haplotype associ-
ation P value  0.65) (Table 2).
Discussion
To our knowledge, this is the first study to evaluate a set of






FIG. 1. Daily salivary 17-estradiol concentrations (geometric means)
in midmenstrual cycle (aligned cycle day, 7, 6) for women
categorized by CYP17 rs2486758 genotype and tertiles of metabolic
risk factors. Major allele, homozygote; minor allele, hetero- and
homozygote. A, Waist circumference. Major allele and lower tertile
(n  32), middle tertile (n  41), upper tertile (n  38); minor allele
and lower tertile (n  23), middle tertile (n  27), upper tertile (n 
28). B, Total cholesterol/HDL-C ratio. Major allele and lower tertile (n 
36), middle tertile (n  34), upper tertile (n  38); minor allele and
lower tertile (n  27), middle tertile (n  27), upper tertile (n  22). C,
Fasting triglycerides. Major allele and lower tertile (n  37), middle
tertile (n  38), upper tertile (n  34); minor allele and lower tertile
(n  27), middle tertile (n  24), upper tertile (n  25). D, Mean
arterial pressure calculated by the equation: [(diastolic blood
pressure  2)  systolic blood pressure]/3. Major allele and lower
tertile (n  41), middle tertile (n  34), upper tertile (n  36); minor
allele and lower tertile (n  21), middle tertile (n  28), upper tertile
(n  29). E, HOMA score calculated by the equation: [fasting glucose
(mmol/liter)  fasting insulin (IU/ml)]/22.5. Major allele and lower
tertile (n  39), middle tertile (n  41), upper tertile (n  29); minor
allele and lower tertile (n  22), middle tertile (n  21), upper tertile
(n  33). F, Clustered metabolic score estimated from: waist
circumference, fasting triglycerides, total cholesterol/HDL-C ratio,
blood pressure as per the equation above, and HOMA score as per the
equation above. Major allele and lower tertile (n  43), middle tertile
(n  31), upper tertile (n  34); minor allele and lower tertile (n  22),
middle tertile (n  27), upper tertile (n  27).
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hormone concentrations and metabolic risk factors. We ob-
served a novel association between the CYP17 rs2486758
minor allele and elevated daily levels of free biologically ac-
tive estradiol among premenopausal Norwegian women in
the upper tertile of metabolic risk factors.
Some previous studies have reported increased levels of
salivary and serum estradiol among healthy premeno-
pausal women with the hetero- and homozygote genotype
of the CYP17 rs743572 minor allele (1–3), whereas others
reported inconsistent results (4), as has also been the case
with serum progesterone (1, 4).
CYP17 rs2486758 is localized in the intergenic section
near the 5	 of CYP17, and approximately 40% of trait-as-
sociated SNPs have been found in intergenic regions (13).
Based on current understanding in this field, we can predict
that theCYP17 rs2486758minorallelemay increaseCYP17
expression by effecting gene splicing, transcription factor
binding,or thesequenceofnoncodingRNA(13).Changes in
the feedback sensitivity and adjustment of the estradiol set-
point driven by CYP17 could be a possible explanation for
the observed increase in circulating levels of estradiol, and
this will have to be tested in further studies.
In the present analysis, CYP17 rs2486758 was not as-
sociated with metabolic risk factors and levels of SHBG.
Thus, our data support a true gene-environment interac-
tion, in which only women with the CYP17 rs2486758
minor allele are susceptible to the possible estrogen-en-
hancing effects of a high clustered metabolic score. A sim-
ilar interaction was observed between CYP17 rs743572
and body mass index in a study of serum estradiol (2).
Nutrition and physiological stress have also been reported
to change gene expression through epigenetic mecha-
nisms, and there is indirect evidence of epigenetic regula-
tion of CYP17 from in vitro studies (14). CYP17 expres-
sion in the ovaries depends on complex interactions
between multiple molecular pathways (15). Moreover,
differential tissue-specific regulation of CYP17 in the
ovary and adipose tissue (16) may also have contributed to
the interactions observed in our study.
Physiological studies have shown that nutritional sta-
tus (i.e. overweight) and energy metabolism may regulate
estrogen levels through different mechanisms; increased
energy availability up-regulates ovarian function and hor-
mone secretion in premenopausal years (17). Further-
more, estrogens are formed from androgens in adipose
tissue, and adiposity-associated insulin resistance causes
reduction in the hepatic production of SHBG (18).
The observed interaction between CYP17 and metabolic
risk factors in the present study may be particularly relevant
forbreast cancer. Indeed,because thedisease seems tocluster
in a subset of the female population (19), genetic variation
and interactions with lifestyle-related factors may contribute
to breast cancer risk, but further studies are needed.
In a larger study, no association between CYP17
rs2486758 and breast cancer risk was observed (20). On
the contrary, an increased breast cancer risk has been
linked to CYP17 rs743572 minor allele carriers (21). Nev-
ertheless, several studies have reported conflicting results
and questioned breast cancer susceptibility related to
CYP17 genotypes (6).
Our study suggests that genetically susceptible women
with the CYP17 rs2486758 minor allele may benefit from
the modification of metabolic risk factors for the preven-
tion of breast cancer and other estrogen-related diseases
(i.e. osteoporosis, cardiovascular disease). These are im-
portant public health perspectives considering the world-
wide increase in the prevalence of obesity, type 2 diabetes,
and metabolic syndrome. However, our findings need to
be replicated by others and in populations of different
ethnicities. Also, studies of breast cancer and other disease
outcomes are needed to clarify whether this new knowl-
edge should be incorporated in health care delivery.
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TABLE 2. Haplotype association with salivary
17-estradiol concentrations for the eight selected SNP
in CYP17 in the Norwegian EBBA-I Study (n  203)
Haplotypea Frequency
17-estradiol
P valueDifference 95% CI
AAAGCGAA 0.28 0.00 Ref.
ACGGCGAA 0.19 0.06 0.23, 0.12 0.53
AAAACAGA 0.16 0.03 0.14, 0.21 0.73
AAAGCGAG 0.16 0.25 0.08, 0.43 0.0045
AAAACAGG 0.06 0.17 0.47, 0.13 0.26
GAAAGAGA 0.05 0.06 0.18, 0.31 0.62
ACGACAGA 0.05 0.04 0.3, 0.23 0.79
GCGAGAGA 0.03 0.19 0.15, 0.53 0.28
GAAAGAGG 0.02 0.1 0.33, 0.53 0.65
Test of equality between haplotypes (global haplotype association),
P value  0.65.
a Haplotype order, rs1004467 (AG), rs743575 (AC), rs4919687
(GA), rs3781286 (GA), rs3824755 (CG), rs10786712 (GA),
rs743572 (AG), and rs2486758(AG).
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16. Puche C, José M, Cabero A, Meseguer A 2002 Expression and en-
zymatic activity of the P450c17 gene in human adipose tissue. Eur
J Endocrinol 146:223–229
17. Ziomkiewicz A, Ellison PT, Lipson SF, Thune I, Jasienska G 2008
Body fat, energy balance and estradiol levels: a study based on hor-
monal profiles from complete menstrual cycles. Hum Reprod 23:
2555–2563
18. Key TJ, Allen NE, Verkasalo PK, Banks E 2001 Energy balance and
cancer: the role of sex hormones. Proc Nutr Soc 60:81–89
19. Balmain A, Gray J, Ponder B 2003 The genetics and genomics of
cancer. Nat Genet 33:238–244
20. Setiawan VW, Schumacher FR, Haiman CA, Stram DO, Albanes D,
Altshuler D, Berglund G, Buring J, Calle EE, Clavel-Chapelon F,
Cox DG, Gaziano JM, Hankinson SE, Hayes RB, Henderson BE,
Hirschhorn J, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Kraft P,
Ma J, Le Marchand L, Linseisen J, Lund E, Navarro C, Overvad K,
Palli D, Peeters PH, Pike MC, Riboli E, Stampfer MJ, Thun MJ,
Travis R, Trichopoulos D, Yeager M, Ziegler RG, Spencer Feigelson
H, Chanock SJ 2007 CYP17 genetic variation and risk of breast and
prostate cancer from the National Cancer Institute Breast and Pros-
tate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Bio-
markers Prev 16:2237–2246
21. Chakraborty A, Murthy NS, Chintamani C, Bhatnagar D, Mohil
RS, Sharma PC, Saxena S 2007 CYP17 gene polymorphism and its
association with high-risk north Indian breast cancer patients. J
Hum Genet 52:159–165
J Clin Endocrinol Metab, May 2012, 97(5):E852–E857 jcem.endojournals.org E857





Materials and methods 
Clinical parameters 
All clinical measurements were conducted by two trained nurses at the Clinical Research Center, 
University Hospital of North Norway (UNN), Tromsø, Norway (1). Each participant came to the 
UNN three times during their menstrual cycle for clinical examination, between days 1–5, days 
7–12 and days 21–25. The first visit was on the first day possible after the onset of menstrual 
bleeding, and was the only visit taken into account in the present report. During this first visit 
anthropometric measurements were taken with participants wearing light clothing and no 
footwear. Height was measured to the nearest 0.5 cm, and weight to the nearest 0.1 kg on an 
electronic scale. Body mass index was measured in kg/m2. Waist circumference (cm) was 
measured 2.5 cm above the umbilicus. Blood pressure was measured three times subsequent to a 
5-minute resting period in a sitting position, and the mean of the final two measurements was 
used in the analysis.  
 
Collection and analysis of blood samples 
Morning blood samples were taken at each of the three scheduled visits, after a fasting period that 
started at midnight and included abstaining from smoking and exercise. The present report 
considered data from the first visit only. Glucose, sex- hormone-binding globulin (SHBG) and 
lipid levels were measured in fresh serum at the Department of Clinical Chemistry, UNN (1). 
Serum glucose was measured enzymatically by the hexokinase method. SHBG was measured by 
an immunometric method (Diagnostic Products Corporation (DPC), Bierman GmbH, Bad 
Nauheim, Germany). Fasting triglycerides were assayed by enzymatic hydrolysis with lipase. 
Total cholesterol was determined enzymatically using cholesterol esterase and cholesterol 
oxidase. High-density lipoprotein cholesterol (HDL-C) was quantified by direct assay using PEG-
modified enzymes and dextran sulfate. Insulin was measured at the Hormone Laboratory, Aker 
2 
 
University Hospital, Oslo, Norway, in sera stored at -70°C until analysis by radioimmunoassay 
(RIA) (Linco Research Inc., St. Charles, Missouri, USA). 
 
Collection and analysis of saliva samples 
Participants self-collected daily morning saliva samples at home for one entire menstrual cycle 
starting on the first day of bleeding (1, 4). Hormone assays were run in the Reproductive Ecology 
Laboratory, Harvard University, Cambridge, Massachusettes, USA. 
Salivary 17β-estradiol concentration was assayed for 20 days (reverse cycle days −5 to 
−24; with -1 implicating the last day of the menstrual cycle) and progesterone for 14 days 
(reverse cycle days −1 to −14) of the menstrual cycle using I-125-based RIA kits (Diagnostic 
Systems Laboratories, Webster, TX, USA). All samples were run in duplicate, and all samples 
from a single participant were run together in the same assay, with women randomly assigned to 
assay batches. The sensitivity of the 17β-estradiol assay was 4 pmol/l. Average intra-assay 
variability was 9%, and inter-assay variability ranged from 23% for low pools to 13% for high 
pools. For progesterone, the sensitivity of the essay was 13 pmol/l. Average intra-assay variability 
was 10%, inter-assay variability ranged from 19% for low pools to 12% for high pools.  
Prior to statistical analysis of daily ovarian hormone levels, the cycles of the participants 
were aligned at mid-cycle following published methods (4). Alignment was based on the 
identification of the mid-cycle drop in salivary 17β-estradiol concentration (aligned cycle day 0), 
which provides a reasonable estimate of the day of ovulation. Satisfactory identification of the 
mid-cycle drop in salivary 17β-estradiol concentration could not be made for 14 women. For the 
remaining 189 women with aligned cycles, a “late-follicular” index (mean value aligned cycle 
days -5 to -1), a “luteal” index (mean value aligned cycle days 0 to + 6), a “Mid-menstrual” index 
(mean value aligned cycle days -7 to + 6) were calculated. Maximum peak level refers to the 
highest measured hormone value during the menstrual cycle (aligned cycle day -1). Genotypes 
were equally distributed among women with and without an identified drop day.  
3 
 
SNP selection and genotyping 
DNA was extracted from whole blood using MagAttract DNA Blood Mini M48 kit (Qiagen, 
Oslo, Norway) by the Department of Medical Genetics, UNN. To represent the variability of 
CYP17 in Caucasians, eight single nucleotide polymorphisms (SNPs) (rs1004467, rs743575, 
rs4919687, rs3781286, rs3824755, rs10786712, rs743572, rs2486758) were selected  using the 
Genome Variation Server (LD select) (2-3). The SNPs were selected at an r2 threshold of 0.8 and 
a minor allele frequency of > 5%. TagSNP coverage extends 2 kb upstream and 1kb downstream 
of the gene. Genotyping was performed at the Fred Hutchinson Cancer Research Center, Seattle, 
Washington, USA, using the Illumina Golden Gate platform. Included in the assay were 22 
blinded replicates, and genotype control for the Caucasian population (NA07034). One sample 
failed, with a call frequency < 85% and none of the selected SNPs in CYP17 were monomorphic 
or significantly out of the Hardy-Weinberg Equilibrium. Thus, 203 women were included in the 
present study.  
The eight selected SNPs in CYP17 were organized into four groups, or bins according to 
r2, with one highly correlated tagSNP in each bin to ensure the genetic diversity of that bin in the 
statistical analysis. One SNP from each bin (rs743575, rs3824755, rs743572 and rs2486758) was 
then used in the crude analysis. Homo- and heterozygote genotypes of the minor allele were 
combined into one category using the homozygote genotype of the major allele as the reference 
category (dominant model).  
 
Ethical considerations 
All participating women signed an informed consent form and the study was approved by the 







All hormone values were log transformed prior to regression analysis and back-transformed for 
presentation (geometric means and 95% confidence intervals). Inclusion of height, the only 
covariate associated with genotype, and body mass index in the models did not change the 
regression coefficients of genotypes to any meaningful extent.  
Based on  metabolic scores associated with physical activity (5, 6) and breast cancer risk 
(7) in Norwegian women, and the definition of metabolic syndrome by the International Diabetes 
Federation, which includes waist circumference as the primary measure of central obesity (8), we 
constructed a clustered metabolic score by summarizing z-scores [(individual raw values –
sample mean) / sample standard deviation] of waist circumference, fasting triglycerides, total 
cholesterol/HDL-C ratio, homeostatic model assessement (HOMA) score (9), and mean arterial 
pressure [(2 diastolic blood pressure + 1 systolic blood pressure) / 3]. HOMA score and fasting 
triglycerides were log transformed prior to the calculation of z-scores. This metabolic score was 
considered as a continuous variable with a mean of 0, so that lower values corresponded to a 
more favorable profile. Exploratory factor analysis was used to describe the correlations among 
the variables in the clustered metabolic score, and to determine the number of factors describing 
the covariance structure (10). Kaiser’s criterion (eigenvalue > 1) and Cattell’s scree plot were 
used for factor extraction. The exploratory factor analysis indicated a satisfactory loading (> 
0.400) for all variables except fasting triglycerides (< 0.400). Fasting triglycerides were 
nevertheless kept in the clustered metabolic score because of biological plausibility (Table III).  
Generalized estimating equation models, adjusted for age, with Wald chi-square test 
statistics were used to assess the associations between CYP17 rs2486758 genotypes and daily 
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Supplemental Table I. Allele frequencies and distribution of selected SNPs in CYP17 in the Norwegian 






Allelesb MAF HWEc AAd Aad aad
n (%) n (%) n (%)
rs1004467 104484497 Intron_3 A>G 0.097 0.209 169 (83) 31 (15) 4 (2) 
rs743575 104584896 Intron_2 A>C 0.27 0.910 109 (53) 81 (40) 14 (7) 
rs4919687 104585238 Intron _1 G>A 0.27 0.986 109 (53) 81 (40) 14 (7) 
rs3781286 104585709 Intron_1 G>A 0.37 0.236 86 (42) 86 (42) 32 (16) 
rs3824755 104585839 Intron_1 C>G 0.097 0.209 169 (83) 31 (15) 4 (2) 
rs10786712 104586386 Intron_1 G>A 0.37 0.236 86 (42) 86 (42) 32 (16) 
rs743572 104587142 5' UTR A>G 0.37 0.236 86 (42) 86 (42) 32 (16) 
rs2486758 104587470 Intergenic 
(GVS) 
5' near gene 
A>G 0.24 0.221 121 (60) 67 (33) 15 (7) 
 
SNP, single nucleotide polymorphism; MAF, major allele frequency; HWE, Hardy-Weinberg Equilibrium; A, major allele; a, 
minor allele.  
aAccording to information on dbnSNP home-page: http://www.ncbi.nlm.nih.gov/projects/SNP/. 
bMost frequent to least frequent allele. 
cp-value for HWE (cut off 0.0010). 




Supplemental Table II. Daily salivary 17β-estradiol concentrations by cycle day (geometric 
means, 95% confidence intervals, CI) for women categorized by CYP17 rs2486758 genotypes: 





(n = 111) 
Mean (95% CI) 
Minor allelea
(n = 78) 







Mid-menstruald 14.46 (13.98,14.95) 16.49 (15.81,17.19) 14 0.077 
Luteale 15.28 (14.57,16.03) 17.28 (16.30,18.32) 19 0.035 
Maximum peak levelf 24.83 (22.52,27.38) 28.83 (25.37,32.77) 16 0.061 
 
aMajor allele: homozygote, minor allele: hetero- and homozygote.  
bWald chi-square test. 
cMean values of salivary 17β-estradiol concentration for a given number of aligned cycle days.  
dAligned cycle day -7,+ 6 (n = 189).  
eAligned cycle day 0,+ 6 (n = 189). 





Supplemental Table III.  Relationships among selected risk factors in the clustered metabolic 
scorea. The Norwegian EBBA-I Study (n=203)b 
 
Variable, z-scorec  
 
Factor loadingsd  Uniquenesse 
Waist circumference   0.834 0.304 
Fasting triglycerides 0.332 0.890 
HOMA score 0.603 0.637 
Mean arterial pressure 0.547 0.701 
Total cholesterol/HDL-C ratio 0.752 0.435 
 
 
HDL-C, high-density lipoprotein-cholesterol; HOMA, homeostatic model assessement. 
 
aEstimated from sum of z-scores in each women for: waist circumference (cm), total cholesterol/HDL-C ratio, 
fasting triglycerides mmol/l, mean arterial pressure calculated by the equation:  [2 diastolic blood pressure (mmHg) 
+ 1 systolic pressure (mmHg) / 3], and HOMA score given by the equation: [fasting glucose (mmol/l) x fasting 
insulin (μIU/ml)] / 22.5.  
bNumbers may vary due to missing information.  
cz-score calculation; sample mean subtracted from individual score/raw score, divided by the sample standard 
deviation. 
dFactor 1 from principal component factor analysis; represents weights for variables and correlation between the 
variables and the factor. 

































Supplemental Figure 1. Linkage disequilibrium structure among the eight selected 





















Supplemental Figure 2. Daily salivary 17β-estradiol levels by cycle day (geometric 
means) in mid-menstrual cycle (aligned cycle day -7, + 6) for women categorized by 
CYP17 rs2486758 genotypes; major allele (homozygotes) (n=111) and minor allele 
(homo- and heterozygotes) (n=78).  
 
 
Supplemental Table I.  Allele frequencies and distribution of selected SNPs in CYP17. The Norwegian 






Allelesb MAF HWEc AAd Aad aad
n (%) n (%) n (%)
rs1004467 104484497 Intron_3 A>G 0.097 0.209 169 (83) 31 (15) 4 (2) 
rs743575 104584896 Intron_2 A>C 0.27 0.910 109 (53) 81 (40) 14 (7) 
rs4919687 104585238 Intron _1 G>A 0.27 0.986 109 (53) 81 (40) 14 (7) 
rs3781286 104585709 Intron_1 G>A 0.37 0.236 86 (42) 86 (42) 32 (16) 
rs3824755 104585839 Intron_1 C>G 0.097 0.209 169 (83) 31 (15) 4 (2) 
rs10786712 104586386 Intron_1 G>A 0.37 0.236 86 (42) 86 (42) 32 (16) 
rs743572 104587142 5' UTR A>G 0.37 0.236 86 (42) 86 (42) 32 (16) 
rs2486758 104587470 Intergenic 
(GVS) 
5' near gene 
A>G 0.24 0.221 121 (60) 67 (33) 15 (7) 
 
SNP, single nucleotide polymorphism; MAF, major allele frequency; HWE,  Hardy-Weinberg Equilibrium;  A, major allele, 
a, minor allele.  
aAccording to information on dbnSNP home-page: http://www.ncbi.nlm.nih.gov/projects/SNP/ 
bMost frequent to least frequent allele. 
cp-value for HWE (cut off 0.0010).dDistribution in EBBA study population.  
 
 
Supplemental Table II. Daily salivary 17β-estradiol concentrations by cycle day (geometric 
means, 95% confidence intervals, CI) for women categorized by CYP17 rs2486758 genotypes: 





(n = 111) 
Mean (95% CI) 
Minor allelea
(n = 78) 







Mid-menstruald 14.46 (13.98,14.95) 16.49 (15.81,17.19) 14 0.077 
Luteale 15.28 (14.57,16.03) 17.28 (16.30,18.32) 19 0.035 
Maximum peak levelf 24.83 (22.52,27.38) 28.83 (25.37,32.77) 16 0.061 
 
aMajor allele: homozygote, minor allele: hetero- and homozygote.  
bWald chi-square test. 
cMean values of salivary 17β-estradiol concentration for a given number of aligned cycle days.  
dAligned cycle day -7,+ 6 (n = 189).  
eAligned cycle day 0,+ 6 (n = 189). 
fAligned cycle day -1 (n = 189). 
 
 
Supplemental Table III.  Relationships among selected risk factors in the clustered metabolic 
scorea. The Norwegian EBBA-I Study (n=203)b 
 
Variable, z-scorec  
 
Factor loadingsd  Uniquenesse 
Waist circumference   0.834 0.304 
Fasting triglycerides 0.332 0.890 
HOMA score 0.603 0.637 
Mean arterial pressure 0.547 0.701 
Total cholesterol/HDL-C ratio 0.752 0.435 
 
 
HDL-C, high-density lipoprotein-cholesterol; HOMA, homeostatic model assessement. 
 
aEstimated from sum of z-scores in each women for: waist circumference (cm), total cholesterol/HDL-C ratio, 
fasting triglycerides mmol/l, mean arterial pressure calculated by the equation:  [2 diastolic blood pressure (mmHg) 
+ 1 systolic pressure (mmHg) / 3], and HOMA score given by the equation: [fasting glucose (mmol/l) x fasting 
insulin (μIU/ml)] / 22.5.  
bNumbers may vary due to missing information.  
cz-score calculation; sample mean subtracted from individual score/raw score, divided by the sample standard 
deviation. 
dFactor 1 from principal component factor analysis; represents weights for variables and correlation between the 
variables and the factor. 
eProportion of the common variance of the variable not associated with the factor. 
 
 
 
 
 


